Earnings Releases·Nov 5, 2026, 9:35 AM ET

Lipocine — Third Quarter 2026 Earnings Summary

Q3 2026 revenue surged to $2.3 million from $115,000 in the prior year period, driven by $2.1 million in license/collaboration revenue, while net loss narrowed to $0.7 million from $3.2 million.
Nine-month revenue reached $2.6 million versus $831,000 previously, with R&D expenses rising to $6.9 million due to higher LPCN 1154 study costs, though total liabilities decreased to $2.0 million.
Cash and marketable securities increased to $21.5 million as of September 30, 2026, and approximately $28.5 million as of November 4, 2026, with no debt reported on the balance sheet.
Initiated the BLOOM Phase 3 study for LPCN 1154 (BRLIZIO™) in September 2026 and received FDA confirmation that the NDA package is complete for a 505(b)(2) submission contingent on a positive trial.
Health Canada approved TLANDO in September 2026 with a Canadian launch planned for early 2027, and Pharmalink secured UAE marketing authorization for the product with a similar launch timeline.